Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 10,900 shares, a decrease of 14.8% from the December 15th total of 12,800 shares. Based on an average trading volume of 28,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research note on Wednesday.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock traded up $0.31 during midday trading on Friday, reaching $4.06. The company’s stock had a trading volume of 21,165 shares, compared to its average volume of 41,725. The stock has a market capitalization of $22.02 million, a P/E ratio of -1.44 and a beta of 0.75. The stock’s 50-day simple moving average is $3.34 and its 200-day simple moving average is $3.46. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.11. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. As a group, equities research analysts expect that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.